Document Detail


Chemopreventive actions by enterolactone and 13 VIOXX-related lactone derivatives in H295R human adrenocortical carcinoma cells.
MedLine Citation:
PMID:  19913079     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Cytochrome P450c17 (CYP17) has been linked to various hormone-related diseases, including breast cancer, thus being a potential target for cancer chemoprevention. We studied the naturally occurring phytochemical enterolactone (ENL) and 13 VIOXX-related lactone derivatives (CRI-1 to CRI-13) for their effects on CYP17 activity and expression and on cell cycle status in the human H295R adrenocorticocarcinoma cell line. Of the tested compounds, only CRI-3, -7, -10 and -12 showed to be inhibitors of CYP17 activity in H295R cells. This inhibition was not due to decreased mRNA expression, but was apparently caused by post-translational modification of the CYP17 enzyme. The MAPK kinase (MEK) inhibitor PD98059 induced CYP17 activity by 24%, while co-incubation of the CRI-s with PD98059, reduced CYP17 activity even further than the reduction caused by the CRI-s alone. In addition, CRI-3, -7, -10 and -12 arrested the cell cycle in the G(2)/M phase. The structure-activity similarities of the CRI-s with known micro-tubule binding agents strongly suggest that cell cycle arrest is a result of interaction with tubulin. We conclude that the proposed cancer chemopreventive actions of ENL are not mediated through interaction with CYP17 or cell cycle status. Of the VIOXX-related lactone derivatives, CRI-7 could prove useful in the prevention of hormone-dependent cancers, such as breast cancer, since in vitro it shows low cytotoxicity, it is a potent inhibitor of CYP17 activity and strong inducer of cell cycle arrest.
Authors:
Majorie B M van Duursen; Sandra M Nijmeijer; Somsak Ruchirawat; Martin van den Berg
Related Documents :
9744879 - A morphogenesis checkpoint monitors the actin cytoskeleton in yeast.
12543189 - Mitogen-activated protein kinase inhibitor, pd98059, inhibits rat retinal pigment epith...
12593979 - Cell cycle and cell fate interactions in neural development.
8196659 - Effects of mutant ran/tc4 proteins on cell cycle progression.
21257999 - The impact of poloxamer 407 on the ultrastructure of the liver and evidence for clearan...
9018099 - 17beta-estradiol metabolites affect some regulators of the mcf-7 cell cycle.
15659679 - Induction of rapid detachment in shewanella oneidensis mr-1 biofilms.
17361099 - Programs for cell death: apoptosis is only one way to go.
20832339 - γδ t cells enhance autoimmunity by restraining regulatory t cell responses via an int...
Publication Detail:
Type:  Journal Article     Date:  2009-11-11
Journal Detail:
Title:  Toxicology letters     Volume:  192     ISSN:  1879-3169     ISO Abbreviation:  Toxicol. Lett.     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-02-15     Completed Date:  2010-03-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7709027     Medline TA:  Toxicol Lett     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  271-7     Citation Subset:  IM    
Copyright Information:
Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
Affiliation:
Endocrine Toxicology, Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands. m.vanduursen@uu.nl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
4-Butyrolactone / analogs & derivatives*,  pharmacology
Adrenal Cortex Neoplasms / enzymology*,  physiopathology
Adrenocortical Carcinoma / enzymology*,  physiopathology
Cell Cycle / drug effects
Cell Line, Tumor
Enzyme Induction / drug effects
Flavonoids / pharmacology
Gene Expression / drug effects
Humans
Lactones / pharmacology*
Lignans / pharmacology*
Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors
Neoplasms, Hormone-Dependent / prevention & control
Phytoestrogens / pharmacology*
Protein Processing, Post-Translational / drug effects
Steroid 17-alpha-Hydroxylase / antagonists & inhibitors,  biosynthesis,  drug effects*
Structure-Activity Relationship
Sulfones / pharmacology*
Chemical
Reg. No./Substance:
0/Flavonoids; 0/Lactones; 0/Lignans; 0/PD 98059; 0/Phytoestrogens; 0/Sulfones; 0/rofecoxib; 76543-15-2/2,3-bis(3'-hydroxybenzyl)butyrolactone; 96-48-0/4-Butyrolactone; EC 1.14.99.9/Steroid 17-alpha-Hydroxylase; EC 2.7.12.2/Mitogen-Activated Protein Kinase Kinases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparative Genomics Identifies New Alpha Class Genes within the Avian Glutathione S-transferase Gen...
Next Document:  Lubrication properties of potential alternative lubricants, glycerin fatty acid esters, to magnesium...